← All trials
NCT04669288
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- Feb 28, 2025
- Completion date
- Aug 31, 2025
- First posted
- Dec 16, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 1476
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ArizonaLead sponsor
- New York Presbyterian HospitalCollaborator
- Emory UniversityCollaborator
- University of PennsylvaniaCollaborator
- University of ArizonaReponsible party - principal investigator
- University of ArizonaOverall official - principal investigator
- University of PittsburghCollaborator
- University of UtahOverall official - principal investigator
- University of UtahCollaborator
- University of WisconsinCollaborator
- University of CincinnatiCollaborator
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.